DEMONSTRATION OF OPSONIC ACTIVITY AND IN VIVO PROTECTION AGAINST GROUP B STREPTOCOCCI STREPTOCOCCUS PNEUMONIAE TYPE III BY TYPE 14 ANTISERA

Life-threatening group B streptococcal infections in neonates have become a major problem throughout the United States and many other parts of the world (1). It has been estimated that within the United States,- ~ 15,000 babies each year develop sepsis or meningitis due to this organism, with a high rate of morbidity and mortality (1). Why this disease has emerged as an increasing problem over the…